Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016

S. L. Grupke; J. F. Fraser

doi:10.1039/9781788012539-00242

Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Neuroprotective agents are drugs, outside of those used to re-establish perfusion to an infarcted region of the brain, that aim to salvage or protect vulnerable brain tissue during an insult. These drugs are diverse and can act by inhibiting steps in the apoptotic pathway, scavenging damaging species like free radical oxidative species, reducing inflammatory responses, and changing the extracellular environment, among other mechanisms. In this chapter, we will discuss neuroprotective drugs used in recent human clinical trials for acute ischemic stroke, their mechanisms of action, and potential avenues for future research in the discipline of neuroprotection.

Original language	English
Title of host publication	Drug Discovery for Leishmaniasis
Editors	Svetlana A. Dambinova, Thomas A. Gennarelli, Philip V. Peplow, Thomas A. Gennarelli, Bridget Martinez
Pages	242-262
Number of pages	21
Edition	62
DOIs	https://doi.org/10.1039/9781788012539-00242
State	Published - 2018

Publication series

Name	RSC Drug Discovery Series
Number	62
Volume	2018-January
ISSN (Print)	2041-3203
ISSN (Electronic)	2041-3211

Bibliographical note

Publisher Copyright:
© The Royal Society of Chemistry 2018.

ASJC Scopus subject areas

Drug Discovery

Access to Document

10.1039/9781788012539-00242

Cite this

Grupke, S. L., & Fraser, J. F. (2018). Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016. In S. A. Dambinova, T. A. Gennarelli, P. V. Peplow, T. A. Gennarelli, & B. Martinez (Eds.), Drug Discovery for Leishmaniasis (62 ed., pp. 242-262). (RSC Drug Discovery Series; Vol. 2018-January, No. 62). https://doi.org/10.1039/9781788012539-00242

@inbook{45b87bdf7186436eb926444d7baf5251,

title = "Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016",

abstract = "Neuroprotective agents are drugs, outside of those used to re-establish perfusion to an infarcted region of the brain, that aim to salvage or protect vulnerable brain tissue during an insult. These drugs are diverse and can act by inhibiting steps in the apoptotic pathway, scavenging damaging species like free radical oxidative species, reducing inflammatory responses, and changing the extracellular environment, among other mechanisms. In this chapter, we will discuss neuroprotective drugs used in recent human clinical trials for acute ischemic stroke, their mechanisms of action, and potential avenues for future research in the discipline of neuroprotection.",

author = "Grupke, {S. L.} and Fraser, {J. F.}",

year = "2018",

doi = "10.1039/9781788012539-00242",

language = "English",

series = "RSC Drug Discovery Series",

number = "62",

pages = "242--262",

editor = "Dambinova, {Svetlana A.} and Gennarelli, {Thomas A.} and Peplow, {Philip V.} and Gennarelli, {Thomas A.} and Bridget Martinez",

booktitle = "Drug Discovery for Leishmaniasis",

edition = "62",

}

Grupke, SL & Fraser, JF 2018, Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016. in SA Dambinova, TA Gennarelli, PV Peplow, TA Gennarelli & B Martinez (eds), Drug Discovery for Leishmaniasis. 62 edn, RSC Drug Discovery Series, no. 62, vol. 2018-January, pp. 242-262. https://doi.org/10.1039/9781788012539-00242

Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016. / Grupke, S. L.; Fraser, J. F.
Drug Discovery for Leishmaniasis. ed. / Svetlana A. Dambinova; Thomas A. Gennarelli; Philip V. Peplow; Thomas A. Gennarelli; Bridget Martinez. 62. ed. 2018. p. 242-262 (RSC Drug Discovery Series; Vol. 2018-January, No. 62).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Chapter 14

T2 - Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016

AU - Grupke, S. L.

AU - Fraser, J. F.

PY - 2018

Y1 - 2018

N2 - Neuroprotective agents are drugs, outside of those used to re-establish perfusion to an infarcted region of the brain, that aim to salvage or protect vulnerable brain tissue during an insult. These drugs are diverse and can act by inhibiting steps in the apoptotic pathway, scavenging damaging species like free radical oxidative species, reducing inflammatory responses, and changing the extracellular environment, among other mechanisms. In this chapter, we will discuss neuroprotective drugs used in recent human clinical trials for acute ischemic stroke, their mechanisms of action, and potential avenues for future research in the discipline of neuroprotection.

AB - Neuroprotective agents are drugs, outside of those used to re-establish perfusion to an infarcted region of the brain, that aim to salvage or protect vulnerable brain tissue during an insult. These drugs are diverse and can act by inhibiting steps in the apoptotic pathway, scavenging damaging species like free radical oxidative species, reducing inflammatory responses, and changing the extracellular environment, among other mechanisms. In this chapter, we will discuss neuroprotective drugs used in recent human clinical trials for acute ischemic stroke, their mechanisms of action, and potential avenues for future research in the discipline of neuroprotection.

UR - http://www.scopus.com/inward/record.url?scp=85038442307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038442307&partnerID=8YFLogxK

U2 - 10.1039/9781788012539-00242

DO - 10.1039/9781788012539-00242

M3 - Chapter

AN - SCOPUS:85038442307

T3 - RSC Drug Discovery Series

SP - 242

EP - 262

BT - Drug Discovery for Leishmaniasis

A2 - Dambinova, Svetlana A.

A2 - Gennarelli, Thomas A.

A2 - Peplow, Philip V.

A2 - Gennarelli, Thomas A.

A2 - Martinez, Bridget

ER -

Chapter 14: Testing and Mechanisms of Neuroprotective Agents for Cerebral Ischemic Injury in Clinical Trials, 2010-2016

Abstract

Publication series

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this